Federated Hermes Inc. Sells 79,594 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Federated Hermes Inc. decreased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 90.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,534 shares of the biotechnology company's stock after selling 79,594 shares during the period. Federated Hermes Inc.'s holdings in Enanta Pharmaceuticals were worth $49,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth approximately $26,000. Intech Investment Management LLC acquired a new stake in Enanta Pharmaceuticals during the 4th quarter valued at $58,000. Wells Fargo & Company MN raised its stake in Enanta Pharmaceuticals by 69.6% during the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock valued at $91,000 after purchasing an additional 6,518 shares during the period. AlphaQuest LLC increased its stake in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after acquiring an additional 3,137 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Enanta Pharmaceuticals by 10.5% in the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock worth $213,000 after acquiring an additional 3,501 shares during the last quarter. Institutional investors own 94.99% of the company's stock.

Analyst Ratings Changes

ENTA has been the subject of several analyst reports. JMP Securities restated a "market outperform" rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Down 2.8 %

Shares of Enanta Pharmaceuticals stock traded down $0.16 during trading on Thursday, reaching $5.45. 45,198 shares of the company were exchanged, compared to its average volume of 405,298. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $17.24. The business has a 50-day moving average price of $6.22 and a 200-day moving average price of $7.39. The firm has a market capitalization of $116.16 million, a price-to-earnings ratio of -1.10 and a beta of 0.69.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Insider Activity

In other Enanta Pharmaceuticals news, CEO Jay R. Luly purchased 45,000 shares of the business's stock in a transaction dated Wednesday, February 12th. The shares were bought at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.89% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.